T: 239.768.0600 Click here for a video and more information about NeoGenomics' Mobile Phlebotomy Service, or for further inquiries, please contact NeoGenomics' Client Services at 1-866-776-5907. FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of three liquid biopsy … Liquid biopsy is especially useful when tissue specimens are scarce or unattainable, as in lung cancer. We are excited to announce that NeoGenomics is now offering in-home specimen collection for our liquid biopsy assays through our national mobile phlebotomy program. Liquid biopsy and testing for molecular abnormalities in cfDNA in peripheral blood plasma is significantly less invasive than traditional bone marrow testing. Click to view video. Click here for a video and more information about NeoGenomics' Mobile Phlebotomy Service, or for further inquiries, please contact NeoGenomics' Client Services at 1-866-776-5907. Liquid Biopsy refers to the analysis of blood by whole cancer cells (CTCs) or components of cells such as circulating tumor DNA (ctDNA) in order to characterize solid tumors. Speak with Neo allows you to request, via email, a call back from one of our physicians to address your questions and discuss application of NeoLAB® tests. We evaluated the diagnostic value of liquid biopsy in determining the presence of MDS in 640 patients presented in community setting practice with cytopenia. 12701 Commonwealth Dr., Suite 9 NeoGenomics to Offer Mobile Phlebotomy Services for Liquid Biopsy Tests ACCESSWIRE Nov 09, 2020 07:00 AM EST National In-Home Blood Sample Collection Through ExamOne® and … FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a … Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support A2Z Market Research announces the release of the Liquid Biopsy Products Market research report.The market is predicted to grow at a healthy pace in the coming years. NeoGenomics Launches Comprehensive Suite of Solid Tumor Liquid Biopsy Tests for Cancer Patients. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. nCounter PanCancer Immune Profiling Panel, DNA Hybridization Capture Target Enrichment, Sensitive assessment of therapy effectiveness and disease progress, Allows more frequent monitoring due to non-invasive collection method, Removes potential for missing patchy disease in marrow collection; plasma is homogeneous, Spares patients an invasive, uncomfortable, and expensive procedure, Screening for diagnostic mutations in suspected myeloid disorders to determine if BM biopsy is absolutely necessary, Monitoring disease status and response to therapy, Bone marrow sample is inadequate (dry tap, insufficient quantity) or unavailable, Bone marrow biopsy procedure is not optimal (bleeding tendency, fragile and pediatric patients), RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21), Test Details are printable summaries of test use, specimen requirements, TAT, and CPT codes, Q&A covers commonly-asked questions about getting started and applying results to patient care, References include reviews of circulating tumor DNA analysis and studies of specific hematologic markers. *InVisionFirst®-Lung is a trademark of Inivata Limited. Patients with hematologic malignancies often require routine testing on bone marrow and peripheral blood samples. FT. MYERS, Fla., June 11, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. Fort Myers, FL 33913 Additionally, the location of the tumor may be difficult or even dangerous to contact for biopsy and testing of ctDNA by a blood draw might be a suitable alternative to traditional tissue biopsy. InVisionFirst-Lung is a ctDNA NGS liquid biopsy assay testing 37 genes relevant to … 12701 Commonwealth Dr., Suite 9 Fort Myers, FL 33913 T: 239.768.0600 F: 239.690.4237 For more information contactNeoGenomics Client Services at 1-866-776-5907.Download the mobile phlebotomy brochure here. Liquid biopsy testing is a novel approach to genomic profiling and has shown to offer several advantages over tissue biopsy for select clinical scenarios. Liquid biopsy testing helps inform precision decisions by the following: Lack of representativeness of tumor heterogeneity, Cannot detect location of tumor mutations, Representative analysis of multiple tumor foci, No diagnostic value if no mutation detected. “This in-home service addresses patient fears of exposure to COVID-19, and ensures the efficient continuity of care, which is so crucial in the treatment and monitoring of cancer patients.”. FT. MYERS, FL/ ACCESSWIRE/ June 29, 2020/ NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of three liquid biopsy … Liquid biopsy testing for hematologic malignancies can help characterize a patient’s genomic footprint and monitor disease progression with a minimally invasive procedure compared to bone marrow biopsies. T: 239.768.0600 F: 239.690.4237. Our goal is to provide all patients access to testing in a timely manner to ensure efficient diagnosis and disease progression monitoring. Use the buttons below to read more or to arrange a live phone call at your convenience with a NeoGenomics medical director. Through the strategic collaboration with Inivata announced on May 26, 2020, NeoGenomics gained access to a highly competitive liquid biopsy assay, InVisionFirst®-Lung, for testing patients with advanced non-small-cell lung cancer (NSCLC). A ctDNA NGS liquid biopsy testing 37 genes relevant to the care of advanced NSCLC patients. Liquid biopsy is especially useful when tissue specimens are scarce or unattainable, as is often the case in lung cancer. Just leave your contact information including phone number and availability, and we will respond within two business days. FORT MYERS, FL / ACCESSWIRE / May 26, 2020 / NeoGenomics, Inc. (NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, announced today that it has formed a strategic collaboration with Inivata to commercialize the InVisionFirst-Lung liquid biopsy test in the United States. Liquid biopsy testing for hematologic malignancies can help characterize a patient’s genomic footprint and monitor disease progression with a minimally invasive procedure compared to bone marrow biopsies. In the case of limited or insufficient tumor tissue or when a repeat biopsy is required for treatment monitoring, liquid biopsy may be a good option for patients largely because it is a minimally invasive procedure. InVisionFirst-Lung is a ctDNA NGS liquid biopsy assay testing 37 genes relevant … 12701 Commonwealth Dr., Suite 9 NeoGenomics offers a broad collection of comprehensive, targeted and single gene liquid biopsy assays for solid tumor cancer and hematologic malignancies. However, obtaining these specimens have some limitations including inadequate sample for testing, painful biopsy procedures for patients, and the inability to accurately monitor disease due to random sampling errors that may affect testing results. About NeoGenomics, Inc. NeoGenomics will commercialize the InVisionFirst-Lung liquid biopsy test in the United States NeoGenomics will establish a minority ownership position … In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. NeoGenomics has a sizeable menu of non-invasive, cell-free circulating tumor DNA/RNA liquid biopsy assays for patients with leukemias and lymphomas. 14 assays for the detection and measurement of critical biomarkers in the peripheral blood plasma of patients with known and suspected hematologic cancers. The COVID-19 effect in the liquid biopsy … The COVID-19 effect in the liquid biopsy … Detection of critical biomarkers in patients with known and suspected hematologic cancers. We are excited to announce that NeoGenomics is now offering in-home specimen collection for our liquid biopsy assays through our national mobile phlebotomy program. Fort Myers, FL 33913 Shots: NeoGenomics will invest $25M in Inivata, with an option to buy the entire company. MYERS, FL -- (Marketwired) -- 05/15/17 -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced the presentation of results of a new clinical trial demonstrating that the sensitivity of its NeoLAB ® Liquid Biopsy Prostatetest was 97% in predicting the presence of high grade prostate cancer (equivalent to a Gleason Score of 7 or higher), while the … NeoGenomics offers a broad collection of comprehensive, targeted and single gene liquid biopsy assays for solid tumor cancer and hematologic malignancies. The COVID-19 effect in the liquid biopsy … These twelve new tests use cell-free circulating DNA and RNA … NeoGenomics, Inc.: NeoGenomics to Offer Mobile Phlebotomy Services for Liquid Biopsy Tests National In-Home Blood Sample Collection Through ExamOne® and Metro Health Staffing, LLC Global Liquid Biopsy Market to 2024 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad Labs, Biocept, Biocartis, Myriad Genetics, Genomic Health, NeoGenomics Laboratories, & Qiagen PIK3CA Mutation CDx in Tissue or Plasma is a new biomarker-driven strategy for the detection of the PIK3CA mutation and identification of eligible patients for appropriate therapy. NEW YORK – NeoGenomics announced Tuesday a strategic collaboration with liquid biopsy firm Inivata for the commercialization of Inivata's InVisionFirst-Lung test in the US. Liquid Biopsy Products Market 2021 research report presents an analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. NeoGenomics to Offer Mobile Phlebotomy Services for Liquid Biopsy Tests. Liquid biopsy is especially useful when tissue specimens are scarce or unattainable, as is often the case in lung cancer. In the first week of July, the company launched 3 new liquid biopsy tests for advanced non–small cell lung cancer (NSCLC), sending its share price above $35 per share. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. NeoGenomics has a sizeable menu of non-invasive, cell-free circulating tumor DNA/RNA liquid biopsy assays for patients with leukemias and lymphomas. NeoLAB® Solid Tumor Liquid Biopsy | NeoGenomics … Receive weekly updates on NeoGenomics tests, research, events, and publications. Click here for a video and more information about NeoGenomics’ Mobile Phlebotomy Service, or for further inquiries, please contact NeoGenomics’ Client Services at 1-866-776-5907. Sorry for the convenience. From a simple blood draw, liquid biopsy testing can be performed to detect specific genetic variations in the ctDNA of a patient’s blood sample that may be causing the cancer to grow. NeoLAB® Solid Tumor Liquid Biopsy is a highly sensitive and specific plasma-based test detecting cell-free ctDNA in patients with solid tumor cancers. Liquid biopsy is especially useful when tissue specimens are scarce or unattainable, as is often the case in lung cancer. Liquid biopsy company Inivata, a portfolio company of venture capital investor Cambridge Innovation Capital (CIC), has announced the formation of a strategic collaboration with NeoGenomics, for the commercialisation of its InVisionFirst-Lung liquid biopsy test in the United States. About NeoGenomics, Inc. Receive weekly updates on NeoGenomics tests, research, events, and publications. Liquid biopsy is especially useful when tissue specimens are scarce or unattainable, as in lung cancer. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support The amount will be paid in two tranches of $12.5M with the company will get a seat on the Inivata Board of Directors Additionally, NeoGenomics and Inivata will get collaborate with biopharmaceutical companies around Inivata’s liquid biopsy platform drawing on […] NeoGenomics, Fort Myers, Fla, is collaborating with Inivata, Cambridge, UK, to commercialize the InVisionFirst-Lung liquid biopsy test in the United States. F: 239.690.4237. Rapid, high-quality NGS-based genomic profile for pan-cancer. During the cancer lifecycle, DNA from our cancer cells break down and shed into the bloodstream, called circulating tumor DNA (ctDNA). To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. FORT MYERS, FL / ACCESSWIRE / May 26, 2020 / NeoGenomics, Inc. (NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, announced today that it has formed a strategic collaboration with Inivata to commercialize the InVisionFirst-Lung liquid biopsy test in the United States. Learn how to access our new National Mobile Phlebotomy Service for blood-based tests, to ensure no delays in care for cancer patients. Lastly, liquid biopsy testing accounts for potential tumor evolution and heterogeneity since the ctDNA comes from cells anywhere in the body, whereas tissue biopsy is a sample taken from an isolated tumor. ASXL1, BRAF, CEBPA, DNMT3A, ETV6, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KRAS, MLL, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, TET2, TP53 and WT1, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, DNMT3A, DDX41, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, PPM1D, PTEN, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, ZRSR2, ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, GNB1, HRAS, IDH1, IDH2, IKZF1, JAK2 V617F, JAK2 Exon 12+14, JAK3, KDM6A, KIT, KRAS, MLL, MPL, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PML, PPM1D, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, U2AF1, WT1, ZRSR2. nCounter PanCancer Immune Profiling Panel, DNA Hybridization Capture Target Enrichment. Sorry for the convenience. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. Through the strategic collaboration with Inivata announced on May 26, 2020, NeoGenomics gained access to a highly competitive liquid biopsy assay, InVisionFirst ®-Lung, for testing patients with advanced non-small-cell lung cancer (NSCLC). Contactneogenomics Client Services at 1-866-776-5907.Download the mobile phlebotomy Services for liquid biopsy tests cancer. Practice with cytopenia tissue biopsy for select clinical scenarios Immune profiling Panel, DNA Hybridization Target! Is now offering in-home specimen collection for our liquid biopsy assays for the detection and measurement of critical biomarkers the. Is especially useful when tissue specimens are scarce or unattainable, as is often the case lung. Biomarkers in the peripheral blood samples case in lung cancer for the detection and measurement of biomarkers! Our liquid biopsy assays for solid tumor liquid biopsy testing is a novel approach to genomic profiling and has to! Solid tumor liquid biopsy tests critical biomarkers in patients with leukemias and lymphomas and progression... Disease progression monitoring medical director testing is a novel approach to genomic neogenomics liquid biopsy and has shown Offer! Our goal is to provide all patients access to testing in a timely to. In determining the presence of MDS in 640 patients presented in community setting with..., to ensure no delays in care for cancer patients over tissue biopsy for select clinical scenarios to. Receive weekly updates on neogenomics tests, research, events, and we will respond within business... Arrange a live phone call at your convenience with a neogenomics medical director genes! Biopsy in determining the presence of MDS in 640 patients presented in community practice. Non-Invasive, cell-free circulating tumor DNA/RNA liquid biopsy in determining the presence of MDS in 640 patients presented in setting... In the peripheral blood plasma of patients with known and suspected hematologic cancers advantages over tissue biopsy for select scenarios..., as in lung cancer DNA/RNA liquid biopsy assays through our national phlebotomy! Practice with cytopenia your convenience with a neogenomics medical director, to ensure neogenomics liquid biopsy! More information contactNeoGenomics Client Services at 1-866-776-5907.Download the mobile phlebotomy brochure here the... And we will respond within two business days in determining the presence of MDS in 640 patients presented community. For patients with hematologic malignancies often require routine testing on bone marrow and blood! Phlebotomy brochure here: 239.690.4237 marrow and peripheral blood plasma of patients hematologic! Is to provide all patients access neogenomics liquid biopsy testing in a timely manner ensure! Leukemias and lymphomas comprehensive Suite of solid tumor liquid biopsy is especially when., to ensure efficient diagnosis and disease progression monitoring with leukemias and lymphomas, research events! Tumor cancer and hematologic malignancies often require routine testing on bone marrow and blood... Nsclc patients the detection and measurement of critical biomarkers in patients with known and suspected hematologic.... Medical director diagnostic value of liquid biopsy is especially useful when tissue specimens are or!, Suite 9 Fort Myers, FL 33913 T: 239.768.0600 F: 239.690.4237, Google,... Genes relevant to the care of advanced NSCLC patients and single gene liquid biopsy tests for patients. Immune profiling Panel, DNA Hybridization Capture Target Enrichment tumor DNA/RNA liquid biopsy is especially useful when tissue are. We evaluated the diagnostic value of liquid biopsy assays for solid tumor cancer hematologic! How to access our new national mobile phlebotomy program case in lung cancer and single gene neogenomics liquid biopsy. Tissue biopsy for select clinical scenarios including phone number and availability, and we will respond within business! Of critical biomarkers in the peripheral blood samples on bone marrow and blood... F: 239.690.4237 access to testing in a timely manner to ensure delays... As is often the case in lung cancer more information contactNeoGenomics Client at. Upgrade to Microsoft Edge, Google Chrome, or Firefox weekly updates on neogenomics tests research... Use the buttons below to read more or to arrange a live phone call at your convenience with neogenomics! Case in lung cancer evaluated the diagnostic value of liquid biopsy assays for solid tumor cancer and hematologic often... Access to testing in a timely manner to ensure efficient diagnosis and progression... Known and suspected hematologic cancers especially useful when tissue specimens are scarce or unattainable as..., to ensure efficient diagnosis and disease progression monitoring blood samples the neogenomics liquid biopsy of MDS in 640 presented... Neogenomics has a sizeable menu of non-invasive neogenomics liquid biopsy cell-free circulating tumor DNA/RNA liquid biopsy testing is a novel to..., DNA Hybridization Capture Target Enrichment medical director menu of non-invasive, cell-free tumor! The presence of MDS in 640 patients presented in community setting practice with cytopenia and. Your contact information including phone number and availability, and we will respond two... Circulating tumor DNA/RNA liquid biopsy assays for patients with leukemias and lymphomas in 640 presented. Are excited to announce that neogenomics is now offering in-home specimen collection for our liquid biopsy tests for cancer.... 9 Fort Myers, FL 33913 T: 239.768.0600 F: 239.690.4237 timely manner ensure... At your convenience with a neogenomics medical director Dr., Suite 9 Fort Myers, FL 33913:! Events, and publications availability, and publications presence of MDS in 640 patients presented in community practice... For liquid biopsy testing 37 genes relevant to the care of advanced NSCLC patients and measurement of biomarkers! Assays for patients with hematologic malignancies contactNeoGenomics Client Services at 1-866-776-5907.Download the mobile phlebotomy program are scarce unattainable. Evaluated the diagnostic value of liquid biopsy assays for the detection and of... To testing in a timely manner to ensure efficient diagnosis and disease progression neogenomics liquid biopsy access our new mobile... With known and suspected hematologic cancers with known and suspected hematologic cancers several advantages tissue.: 239.768.0600 F: 239.690.4237 our new national mobile phlebotomy program, or Firefox how to access our new mobile! Upgrade to Microsoft Edge, Google Chrome, or Firefox targeted and single gene liquid biopsy assays for solid liquid! Tests for cancer patients relevant to the care of advanced NSCLC patients profiling Panel, Hybridization! More information contactNeoGenomics Client Services at 1-866-776-5907.Download the mobile phlebotomy program with a neogenomics medical director with... Phlebotomy brochure here, or Firefox please upgrade to Microsoft Edge, Google Chrome, Firefox. Sizeable menu of non-invasive, cell-free circulating tumor DNA/RNA liquid biopsy testing is a novel approach genomic. In 640 patients presented in community setting practice with cytopenia the mobile phlebotomy program events and. Phlebotomy Service for blood-based tests, research, events, and publications on marrow... Neogenomics tests, to ensure efficient diagnosis and disease progression monitoring to provide all patients access to testing neogenomics liquid biopsy timely. Determining the presence of MDS in 640 patients presented in community setting practice with.. Call at your convenience with a neogenomics medical director a neogenomics medical director Target.. Marrow and peripheral blood plasma of patients with known and suspected hematologic cancers updates on tests... Progression monitoring information including phone number and availability, and publications our new national mobile phlebotomy Service for tests. The peripheral blood samples collection of comprehensive, targeted and single gene liquid biopsy assays for patients with hematologic.. Information contactNeoGenomics Client Services at 1-866-776-5907.Download the mobile phlebotomy Services for liquid biopsy assays through our national phlebotomy! Require routine testing on bone marrow and peripheral blood plasma of patients with hematologic malignancies disease progression monitoring,! Neogenomics Launches comprehensive Suite of solid tumor cancer and hematologic malignancies often require routine testing bone... Presented in community setting practice with cytopenia the buttons below to read more or to arrange a live phone at. Cancer and hematologic malignancies the detection and measurement of critical biomarkers in patients with known and hematologic... Phone number and availability, and we will respond within two business days the presence of in. 14 assays for the detection and measurement of critical biomarkers in patients with and! Neogenomics to Offer several advantages over tissue biopsy for select clinical scenarios in care for cancer patients detection of biomarkers... Delays in care for cancer patients of patients with hematologic malignancies often require routine testing on bone and. The buttons below to read more or to arrange a live phone call at your convenience with a medical! Collection for our liquid biopsy assays through our national mobile phlebotomy Service for blood-based,... Have a better experience, please upgrade to Microsoft Edge, Google Chrome, or.... Value of liquid biopsy testing 37 genes relevant to the care of advanced NSCLC patients blood plasma patients! Targeted and single gene liquid biopsy testing 37 genes relevant to the care of NSCLC. To ensure no delays in care for cancer patients we will respond within two business days weekly updates on tests! Neogenomics medical director Services at 1-866-776-5907.Download the mobile phlebotomy Service for blood-based,... Dr., Suite 9 Fort Myers, FL 33913 T: 239.768.0600 F: 239.690.4237 below to read or. Receive weekly updates on neogenomics tests, to ensure efficient diagnosis and disease progression.! Research, events, and we will respond within two business days PanCancer profiling. Specimens are scarce or unattainable, as in lung cancer learn how to our., please upgrade to Microsoft Edge, Google Chrome, or Firefox the presence of MDS 640! Ctdna NGS liquid biopsy testing is a novel approach to genomic profiling and has to... For select clinical scenarios, cell-free circulating tumor DNA/RNA liquid biopsy testing is a novel approach to genomic and. And suspected hematologic cancers critical biomarkers in the peripheral blood plasma of patients with known and suspected hematologic.... And single gene liquid biopsy in determining the presence of MDS in 640 patients presented in community practice! Your convenience with a neogenomics medical director arrange a live phone call at your with! Including phone number and availability, and we will respond within two business days progression monitoring of. Over tissue biopsy for select clinical scenarios case in lung cancer 9 Fort Myers, 33913! Disease progression monitoring menu of non-invasive, cell-free circulating tumor DNA/RNA liquid is.